Conference Call and Webcast on Monday, May 12, 2014 at 4:30 p.m. Eastern
Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR) today announced that it will
host a conference call and webcast to report first quarter 2014
operational and financial results. The webcast will take place on
Monday, May 12, 2014 at 4:30 p.m. Eastern Time.
The call can be accessed by dialing (877) 312-7508 (domestic) or (253)
237-1184 (international) five minutes prior to the start of the call and
providing access code 29900745. A live, listen-only webcast of the
conference call can be accessed on the investor relations section of the
Esperion website at www.investor.esperion.com/events.
A webcast replay of the call will be available approximately two hours
after completion of the call and will be archived on the company's
website for two weeks.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the
treatment of patients with hypercholesterolemia and other
cardiometabolic risk markers. ETC-1002, Esperion's lead product
candidate, is a unique, first-in-class, orally available, once-daily
small molecule designed to lower LDL-cholesterol levels and avoid the
side effects associated with the currently-available LDL-cholesterol
lowering therapies. ETC-1002 is being developed primarily for patients
intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b
clinical trials for ETC-1002 are currently underway and build upon a
successful and comprehensive Phase 1 and Phase 2 program. For more
information, please visit www.esperion.com.
Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media